The Family Firm’s Bio-Rad Laboratories Class A BIO Stock Holding History

The Family Firm’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14	Closed	-$3.82K	–	274
2024 Q2	$3.82K	Buy	+14	New	+$4.07K	﹤0.01%	763

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

The Family Firm's BIO Position: Q3 2024 in Review

The Family Firm sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2024, closing a stake of 14 shares — an estimated $3.82K sold.

The Family Firm first reported a position in BIO in Q2 2024 and held it in 1 quarter. The position peaked at $3.82K in Q2 2024. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

The Family Firm reported no remaining Bio-Rad Laboratories Class A position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 14 Bio-Rad Laboratories Class A shares in Q3 2024, an estimated $3.82K.
The Family Firm first reported a position in Bio-Rad Laboratories Class A in Q2 2024 and held it in 1 quarter.
The Family Firm's Bio-Rad Laboratories Class A position peaked at $3.82K in Q2 2024.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.